Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $37.31 and last traded at $37.27, with a volume of 39655 shares traded. The stock had previously closed at $36.08.
Analyst Ratings Changes
MPLT has been the topic of a number of recent research reports. Needham & Company LLC boosted their target price on Maplight Therapeutics from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Stifel Nicolaus raised their price target on Maplight Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Craig Hallum reduced their price target on Maplight Therapeutics from $43.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, June 23rd. Benchmark reissued a “buy” rating on shares of Maplight Therapeutics in a research note on Monday, June 22nd. Finally, Raymond James Financial assumed coverage on Maplight Therapeutics in a report on Wednesday, June 24th. They issued a “strong-buy” rating and a $46.00 price objective on the stock. Four analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Maplight Therapeutics presently has a consensus rating of “Buy” and an average price target of $38.80.
Check Out Our Latest Research Report on Maplight Therapeutics
Maplight Therapeutics Price Performance
Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). Analysts expect that Maplight Therapeutics, Inc. will post -5.13 earnings per share for the current year.
Insider Transactions at Maplight Therapeutics
In other Maplight Therapeutics news, CEO Christopher A. Kroeger sold 118,235 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the completion of the sale, the chief executive officer directly owned 1,394,094 shares in the company, valued at $37,905,415.86. This represents a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Erin Pennock Foff sold 24,052 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total value of $691,735.52. Following the completion of the sale, the insider directly owned 350,497 shares in the company, valued at approximately $10,080,293.72. This represents a 6.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 495,244 shares of company stock worth $14,079,461. Corporate insiders own 3.80% of the company’s stock.
Hedge Funds Weigh In On Maplight Therapeutics
Large investors have recently made changes to their positions in the business. Fcpm Iii Services B.V. acquired a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $56,672,000. T. Rowe Price Investment Management Inc. bought a new position in Maplight Therapeutics in the 4th quarter worth approximately $49,154,000. Goldman Sachs Group Inc. acquired a new position in shares of Maplight Therapeutics during the fourth quarter worth approximately $34,026,000. Nan Fung Group Holdings Ltd acquired a new position in shares of Maplight Therapeutics during the fourth quarter worth approximately $17,060,000. Finally, 5AM Venture Management LLC bought a new stake in shares of Maplight Therapeutics in the fourth quarter valued at approximately $16,687,000.
Maplight Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Read More
- Five stocks we like better than Maplight Therapeutics
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
